Applied Spectral Imaging and WaveSense to Cooperate in Molecular Pathology and Cytogenetic FISH
Delivering a state-of-the-art integrated computerized analysis instrument and cell enrichment solution
Carlsbad, California and Irvine, California , April 22, 2013 –Applied Spectral Imaging Inc. (ASI) and WaveSense Inc. have entered into an agreement in which both companies will engage in combined sales and marketing of the GenASIs imaging and analysis instrument by ASI and the EpiSEP cell recovery and enrichment solution by WaveSense. The combined solution delivers an integrated cell capturing solution and computerized instrument to detect, image and analyze the captured cells.
“We are excited to be working with WaveSense to deliver combined state-of-the-art computerized imaging and analysis using ASI’s GenASIs platforms with WaveSense’s EpiSEP cell recovery and enrichment product. Our combined offering for molecular pathology and cytogenetics leverages the imaging and analysis accuracy, speed and quality results of GenASIs with the improved workflow, flexibility, efficiency and simplicity of EpiSEP and this, in turn, brings unparalleled value to our customers” said Limor Shiposh CEO of ASI Inc.
“Personalized medicine challenges laboratories to continuously evolve and expand their molecular pathology applications rapidly and cost effectively. WaveSense and ASI platforms provide a straightforward versatile environment for optimizing existing applications or implementing new applications. The diagnostic specificity, diagnostic sensitivity, workflow efficiencies, and robustness that our combined platforms can assert on an application are tremendous. The GenASIs platform is very accessible and user friendly, it expertly complements the simplicity and ease of use of our EpiSEP platform. The new combined platform is ideally suited for containing, imaging and analyzing paramagnetic labeled target cells within the EpiSEP slide.” Said Chris Feistel CEO of WaveSense Inc.
ASI and WaveSense have confirmed the combined solution’s effectiveness in performing semi-automated FISH analysis of paramagnetic labeled target cells. Target cells may be retrieved, enriched, imaged and analyzed in urine, bone marrow, blood, needle aspiration, abdominal ascites, lymph node, culture and pleural effusion specimens.
About Applied Spectral Imaging
Applied Spectral Imaging (ASI) makes patient care better through advanced biomedical imaging.
GenASIs by ASI is FDA cleared for FISH clinical applications such as ALK, UroVysion, HER2/neu, CEP XY and Karyotyping. ASI complies with major regulatory requirements and international quality standards.
ASI has been one of the industry's leading microscopy imaging solution providers since 1993, with over 30 registered patents in the US, Europe and Japan and over 2,500 systems deployed worldwide. With worldwide offices in the US, Europe and Asia, ASI has built a global network of over 50 distributors.
WaveSense develops, manufactures, and markets award winning breakthrough analytical nanotechnologies for use in cellular and molecular assay markets. Some applications we actively engage in consist of drug discovery, companion diagnostic development, veterinary diagnostics, and rare cell detection in blood, urine, and bone marrow.
# # #
For More Information Contact –
Applied Spectral Imaging Inc.
Mrs. Limor Shiposh, Chief Executive Officer
Phone: +1 (760) 929 2840
15339 Barranca Parkway
Irvine, California, USA 92618
Tel: +1 (949) 341-1980